VTRS

Viatris Inc.
$16.27
-0.07 (-0.43%)
Mkt Cap 18.83B
Volume 6,938,109
52W Range 8.63-17.53
Sector Healthcare
Beta 0.90
EPS (TTM) -0.26
P/E Ratio -4.15
Revenue (TTM) 14.56B
Rev Growth (5Y) +3.7%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
What we estimate one share is worth
$22.11
Undervalued moderate signal
26.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
22.7 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 14.30B 14.74B 15.43B 16.26B 17.89B 11.95B 11.50B 11.43B 11.91B 11.08B 9.43B 7.72B
Net Income (3.51B) (634.20M) 54.70M 2.08B (1.27B) (669.90M) 16.80M 352.50M 696.00M 480.00M 847.60M 929.40M
EPS -3.00 -0.53 0.05 1.71 -1.05 -1.11 0.03 0.69 1.30 0.94 1.80 2.49
Free Cash Flow 1.94B 1.98B 2.33B 2.51B 2.51B 550.60M 1.40B 2.09B 1.79B 1.66B 1.65B 689.50M
FCF / Share 1.65 1.66 1.94 2.07 2.07 0.92 2.50 4.05 3.34 3.18 3.31 1.74
Operating CF 2.32B 2.30B 2.80B 3.00B 3.02B 1.23B 1.80B 2.34B 2.06B 2.05B 2.01B 1.01B
Total Assets 37.19B 41.50B 47.69B 50.02B 54.84B 61.55B 31.26B 32.73B 35.81B 34.73B 22.27B 15.82B
Total Debt 14.70B 14.31B 18.37B 19.53B 23.36B 26.16B 12.92B 13.82B 14.66B 15.47B 7.31B 8.48B
Cash & Equiv 1.35B 734.80M 991.90M 1.26B 701.20M 844.40M 475.60M 388.10M 292.10M 998.80M 1.24B 225.50M
Book Value 14.71B 18.64B 20.47B 21.07B 20.49B 22.95B 11.88B 12.17B 13.31B 11.12B 9.76B 3.26B
Return on Equity -0.24 -0.03 0.00 0.10 -0.06 -0.03 0.00 0.03 0.05 0.04 0.09 0.29
VTRS News
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Jul 10, 2026 06:41 AM · zacks.com
VTRS or DHR: Which Is the Better Value Stock Right Now?
Jul 09, 2026 08:40 AM · zacks.com
Should Value Investors Buy Viatris (VTRS) Stock?
Jul 09, 2026 06:41 AM · zacks.com
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
Jul 07, 2026 09:19 AM · 247wallst.com
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Jul 06, 2026 09:09 AM · fool.com
Viatris (VTRS) is a Great Momentum Stock: Should You Buy?
Jul 02, 2026 09:01 AM · zacks.com
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Jul 01, 2026 02:59 AM · prnewswire.com
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Jun 29, 2026 06:50 AM · zacks.com
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Jun 29, 2026 02:59 AM · prnewswire.com
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Jun 24, 2026 06:41 AM · zacks.com